Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 2
1963 3
1964 2
1965 1
1966 4
1967 4
1968 2
1969 2
1970 2
1971 1
1972 1
1973 2
1974 3
1975 5
1976 7
1977 4
1978 4
1979 8
1980 17
1981 2
1982 10
1983 15
1984 10
1985 5
1986 8
1987 8
1988 19
1989 13
1990 9
1991 6
1992 11
1993 19
1994 21
1995 33
1996 32
1997 28
1998 21
1999 36
2000 28
2001 24
2002 23
2003 30
2004 25
2005 39
2006 29
2007 41
2008 33
2009 45
2010 38
2011 59
2012 68
2013 44
2014 42
2015 50
2016 55
2017 36
2018 44
2019 59
2020 55
2021 52
2022 45
2023 16

Text availability

Article attribute

Article type

Publication date

Search Results

1,264 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Thompson AJ, et al. Among authors: hartung hp. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Lancet Neurol. 2018. PMID: 29275977 Review.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. Among authors: hartung hp. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Acquired aplastic anemia in children.
Hartung HD, Olson TS, Bessler M. Hartung HD, et al. Pediatr Clin North Am. 2013 Dec;60(6):1311-36. doi: 10.1016/j.pcl.2013.08.011. Epub 2013 Oct 16. Pediatr Clin North Am. 2013. PMID: 24237973 Free PMC article. Review.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. Among authors: hartung hp. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: hartung hp. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Immune-mediated neuropathies.
Kieseier BC, Mathey EK, Sommer C, Hartung HP. Kieseier BC, et al. Among authors: hartung hp. Nat Rev Dis Primers. 2018 Oct 11;4(1):31. doi: 10.1038/s41572-018-0027-2. Nat Rev Dis Primers. 2018. PMID: 30310069 Review.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: hartung hp. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Bar-Or A, et al. Among authors: hartung hp. Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17. Trends Mol Med. 2020. PMID: 31862243 Free PMC article. Review.
New drugs for multiple sclerosis: new treatment algorithms.
Cree BAC, Hartung HP, Barnett M. Cree BAC, et al. Among authors: hartung hp. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. doi: 10.1097/WCO.0000000000001063. Curr Opin Neurol. 2022. PMID: 35674067 Review.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: hartung hp. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e919. doi: 10.1212/NXI.0000000000000919. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33411674 Free PMC article. Review.
1,264 results